

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

| | | |
|---|---|--|
| 1. Name and Address of Reporting Person* <u>Boulding Mark Elliott</u> (Last) (First) (Middle) C/O PTC THERAPEUTICS, INC. 500 WARREN CORPORATE CENTER DRIVE (Street) WARREN NJ 07059 (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>PTC THERAPEUTICS, INC. [PTCT]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EXEC. VP AND CLO</u> |
| | 3. Date of Earliest Transaction (Month/Day/Year) 12/02/2024 | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 12/02/2024 | | M ⁽¹⁾ | | 1,960 | A | \$51 | 94,349 | D | |
| Common Stock | 12/02/2024 | | S ⁽¹⁾ | | 1,960 | D | \$52.17 ⁽²⁾ | 92,389 | D | |
| Common Stock | 12/02/2024 | | M ⁽¹⁾ | | 83,640 | A | \$51 | 176,029 | D | |
| Common Stock | 12/02/2024 | | S ⁽¹⁾ | | 83,640 | D | \$52.26 ⁽³⁾ | 92,389 | D | |
| Common Stock | 12/03/2024 | | M ⁽¹⁾ | | 600 | A | \$33.02 | 92,989 | D | |
| Common Stock | 12/03/2024 | | S ⁽¹⁾ | | 600 | D | \$53.04 ⁽⁴⁾ | 92,389 | D | |
| Common Stock | 12/03/2024 | | M ⁽¹⁾ | | 7,720 | A | \$33.02 | 100,109 | D | |
| Common Stock | 12/03/2024 | | S ⁽¹⁾ | | 6,315 | D | \$53.14 ⁽⁵⁾ | 93,794 | D | |
| Common Stock | 12/03/2024 | | S ⁽¹⁾ | | 1,405 | D | \$54.05 ⁽⁶⁾ | 92,389 | D | |
| Common Stock | 12/03/2024 | | M ⁽¹⁾ | | 1,988 | A | \$33.02 | 94,377 | D | |
| Common Stock | 12/03/2024 | | S ⁽¹⁾ | | 1,900 | D | \$53.13 ⁽⁷⁾ | 92,477 | D | |
| Common Stock | 12/03/2024 | | S ⁽¹⁾ | | 88 | D | \$54.14 | 92,389 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|--|--------|--|-----------------|---|--|--|---|--|-------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | | | | | | Title |
| Stock Option (Right to Buy) | \$51 | 12/02/2024 | | M ⁽¹⁾ | | | 1,960 | (8) | 01/02/2025 | Common Stock | 1,960 | \$0 | 83,640 | D | |
| Stock Option (Right to Buy) | \$51 | 12/02/2024 | | M ⁽¹⁾ | | | 83,640 | (8) | 01/02/2025 | Common Stock | 83,640 | \$0 | 0 | D | |
| Stock Option (Right to Buy) | \$33.02 | 12/03/2024 | | M ⁽¹⁾ | | | 600 | (8) | 01/02/2029 | Common Stock | 600 | \$0 | 3,070 | D | |
| Stock Option (Right to Buy) | \$33.02 | 12/03/2024 | | M ⁽¹⁾ | | | 7,720 | (8) | 01/02/2029 | Common Stock | 7,720 | \$0 | 61,110 | D | |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|--|-------|--|-----------------|---|--|--|---|--|-------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | | | | | | Title |
| Stock Option (Right to Buy) | \$33.02 | 12/03/2024 | | M ⁽¹⁾ | | | 1,988 | (8) | 01/02/2029 | Common Stock | 1,988 | \$0 | 15,512 | D | |

Explanation of Responses:

- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on October 31, 2023.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$52.00 to \$52.83 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$52.00 to \$52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$53.00 to \$53.09 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$53.00 to \$53.995 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$54.025 to \$54.16 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$53.00 to \$53.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Currently exercisable.

/s/ Avraham S. Adler, Attorney- in-Fact 12/04/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.